

The Board of Directors' of Swedish Orphan Biovitrum AB (publ) statement in accordance with Chapter 19 Section 22 of the Swedish Companies Act

In view of the Board of Directors' proposal to the Annual General Meeting 2023 under items 17.B.I and 17.B.II, respectively, on authorisation for the Board of Directors to decide on a directed offer to acquire all of the company's issued series C shares, the Board of Directors hereby makes the following statement in accordance with Chapter 19 Section 22 of the Swedish Companies Act.

The Board of Directors is convinced that the implementation of the proposed incentive programmes (the "**Programmes**") will be beneficial to both the company and its shareholders. Repurchase of the series C shares constitutes a step in the implementation of the Programmes and the purpose is to create capacity for the company to deliver shares pursuant to the Programmes. The intention is that the repurchased series C shares, following conversion to common shares, shall be transferred to programme participants free of charge as well as transferred on a regulated market in order to cover the cash flow effects associated with the Programmes, mainly social security charges. The shares are thereby intended to secure the company's obligations under the Programmes.

The financial position of the company and of the group as of 31 December 2022 is presented in the annual report for the financial year 2022. The annual report also presents the principles applied for valuation of assets. The company's equity would have been approximately SEK 7 million lower if assets and liabilities had not been valued at actual value in accordance with Chapter 4, Section 14 a of the Annual Reports Act.

The Board of Directors concludes that there will be full coverage for the company's restricted equity also under the assumption that the proposed authorisations for the Board of Directors to decide on the acquisition of own shares are fully utilised. Furthermore, in view of the above, the Board of Directors is of the opinion that the proposed authorisations are justifiable with respect to the amount of the equity required by the nature, scope and risks associated with the business, as well as the company's and the group's consolidation requirements, liquidity and overall financial position. The Board of Directors has also considered other known circumstances, and in doing so has found nothing that suggests that the proposed authorisations for the Board of Directors to decide on the acquisition of own shares are not justifiable.

Stockholm in March 2023

Swedish Orphan Biovitrum AB (publ)

The Board of Directors